Astec LifeSciences Limited Announces Unaudited Standalone and Consolidated Financial Results for the Third Quarter and Nine Months Ended Dec. 31, 2015
January 29, 2016 at 07:40 pm IST
Share
Astec LifeSciences Limited announced unaudited standalone and consolidated financial results for the third quarter and nine months ended Dec. 31, 2015. For the quarter, the parent company reported loss from operations before other income, finance cost & exceptional items of INR 156 million against profit of INR 81 million for the same period of last year. Profit from ordinary activities before tax was INR 233 million against INR 274 million for the same period of last year. Net profit for the period was INR 14.658 million or INR 8.7 per basic and diluted share against INR 10.278 million or INR 2.02 per basic and diluted share for the same period of last year. Net sales/income from operations (net of excise duty) were INR 425 against INR 530 million for the same period of last year.
For the quarter, the parent company reported profit from operations before other income, finance cost & exceptional items of INR 9.8 million against INR 243 million for the same period of last year. Profit from ordinary activities before tax was INR 225.7 million against profit of INR 155 million for the same period of last year. Net loss for the period was INR 150 million or INR 6.49 per basic and diluted share against profit of INR 120 million or INR 7.87 per basic and diluted share for the same period of last year. Net sales/income from operations (net of excise duty) were INR 1,586 against INR 1,610 million for the same period of last year.
For the quarter, the group reported loss from operations before other income, finance cost & exceptional items of INR 156 million against profit of INR 82 million for the same period of last year. Loss from ordinary activities before tax was INR 227 million against INR 46 million for the same period of last year. Net profit for the period was INR 169.9 million or INR 8.69 per basic and diluted share against INR 36 million or INR 1.94 per basic and diluted share for the same period of last year. Net sales/income from operations (net of excise duty) were INR 425 against INR 573 million for the same period of last year.
For the quarter, the group reported profit from operations before other income, finance cost & exceptional items of INR 10 million against INR 247 million for the same period of last year. Loss from ordinary activities before tax was INR 229 million against profit of INR 151 million for the same period of last year. Net loss for the period was INR 153 million or INR 7.83 per basic and diluted share against profit of INR 115.3 million or INR 6.22 per basic and diluted share for the same period of last year. Net sales/income from operations (net of excise duty) were INR 1,709 against INR 1,745 million for the same period of last year.
Astec LifeSciences Limited is an India-based company that is primarily engaged in manufacturing a range of agrochemical active ingredients and pharmaceutical intermediates. The Company operates through the Agrochemicals segment. It manufactures a range of fungicides, insecticides, herbicides, and intermediates for its global customers. The Companyâs products and intermediates includes triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, thorium salts, pyrazaloneâs and heterocyclic sulfonyl chlorides.
ASTEC LIFESCIENCES LIMITED 
